Robert A. Lafyatis, MD
Adjunct Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology (Arthritis)

MD, University of Cincinnati



Dr. Lafyatis carries out patient oriented research into the cause and treatment of systemic sclerosis. This includes early phase clinical trials into new therapeutic agents in patients with systemic sclerosis. He has been investigating the mechanisms of actions and markers of response for novel therapeutics, such as the B cell depleting agent, rituximab and the immunosuppressant agent, mycophenlate. Additional studies are aimed at identifying biomarkers in systemic sclerosis using microarray gene expression analysis of skin and blood in scleroderma patients. Ongoing biomarker studies include investigation into molecular markers of pulmonary hypertension in systemic sclerosis. Dr. Lafyatis also carries out basic research into the cause of fibrosis and vasculopathy in systemic sclerosis using patient samples and murine disease models. His studies have provided key insights into one widely used model of systemic sclerosis, the tight skin mouse. His studies are currently focused on understanding how autoimmunity and the innate immune system lead to fibrosis and vascular damage. This has recently led to the discovery of increased interferon-regulated gene expression in white blood cells of patients with systemic sclerosis. Ongoing research is aimed at better understanding the cause of altered gene expression by monocytes and other cells in the innate immune system.


A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE DOSES OF BIIB059 IN HEALTHY VOLUNTEERS AND SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
04/09/2015 - 04/08/2020 (Co-PI)
PI: Christina Lam, MD
Biogen Idec

SCLERODERMA CLINICAL REPOSITORY (SCAR)
10/01/2014 - 09/30/2019 (PI)
Regeneron Pharmaceuticals, Inc.

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF IL1-TRAP, RILONACEPT, IN SYSTEMIC SCLEROSIS-A PHASE I/II BIOMARKER TRIAL
12/01/2011 - 02/05/2019 (PI)
Regeneron Pharmaceuticals, Inc.

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, EFFICACY, AND PHARMACOKINETICS OF JBT-101 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
12/01/2015 - 11/30/2018 (Co-PI)
PI: Robert W. Simms, MD
Corbus Pharmaceuticals Holdings, Inc.

ASSET: A PHASE II STUDY TO EVALUATE SUBCUTANEOUS ABATACEPT VS. PLACEBO IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CONTROLLED TRIAL [IMI101-344]
03/31/2015 - 11/30/2018 (PI)
Regents of the University of Michigan Bristol-Myers Squibb

SCLERODERMA WORKSHOP
02/01/2010 - 01/31/2018 (PI)
MedImmune, Inc.

NOX4 INHIBITOR IN SYSTEMIC SCLEROSIS
11/14/2014 - 11/13/2017 (PI)
Mistral Therapeutics, Inc.

NIAMS: CORT
09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5P50AR060780-05

RHEUMATIC DISEASES RESEARCH CORE CENTERS
09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5P30AR061271-05

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TOPICAL C-82 IN SYSTEMIC SCLEROSIS-A PHASE I/II BIOMARKER AND SAFETY TRIAL
04/02/2015 - 04/01/2017 (PI)
PRISM Pharma Co Ltd

Showing 10 of 42 results. Show All Results



Yr Title Project-Sub Proj Pubs
2018 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 5R21AR069285-02
2018 International Workshop on Scleroderma Research 5R13AR053784-08
2018 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 5P50AR060780-07 25
2018 NIAMS: Center for Research Translation (CORT) 3P50AR060780-07S1 25
2018 Administrative Core 5P50AR060780-07-6914 25
2018 Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics 5P50AR060780-07-6918 25
2017 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 1R21AR069285-01A1
2017 International Workshop on Scleroderma Research 7R13AR053784-07
2017 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 2P50AR060780-06A1 25
2017 Administrative Core 2P50AR060780-06A1-6914 25
Showing 10 of 51 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Apostolidis SA, Stifano G, Tabib T, Rice LM, Morse CM, Kahaleh B, Lafyatis R. Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Front Immunol. 2018; 9:2191.View Related Profiles. PMID: 30327649.
     
  2. Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, Simms RW, Lafyatis R. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clin Exp Rheumatol. 2018 Jul-Aug; 36 Suppl 113(4):146-149.View Related Profiles. PMID: 30277862.
     
  3. Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, Jahreis A, Zhang Y, Siegel J, Lafyatis R. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2018 Jun; 70(6):912-919.View Related Profiles. PMID: 29858547.
     
  4. Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis. 2018 Sep; 77(9):1362-1371. PMID: 29853453.
     
  5. Fleury M, Belkina AC, Proctor EA, Zammitti C, Simms RW, Lauffenburger DA, Snyder-Cappione JE, Lafyatis R, Dooms H. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis. Arthritis Rheumatol. 2018 Apr; 70(4):566-577.View Related Profiles. PMID: 29245183.
     
  6. Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD. Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS One. 2018; 13(1):e0189498.View Related Profiles. PMID: 29293537.
     
  7. Sun Z, Wang T, Deng K, Wang XF, Lafyatis R, Ding Y, Hu M, Chen W. DIMM-SC: a Dirichlet mixture model for clustering droplet-based single cell transcriptomic data. Bioinformatics. 2018 01 01; 34(1):139-146. PMID: 29036318.
     
  8. Moll M, Christmann RB, Zhang Y, Whitfield ML, Wang YM, Rice LM, Stratton E, Lafyatis R, Farber HW. Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. 2018. View Publication
  9. Tabib T, Morse C, Wang T, Chen W, Lafyatis R. SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin. J Invest Dermatol. 2018 Apr; 138(4):802-810. PMID: 29080679.
     
  10. Cascio S, Medsger TA, Hawse WF, Watkins SC, Milcarek C, Moreland LW, Lafyatis RA, Fuschiotti P. 14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma. J Allergy Clin Immunol. 2018 Jul; 142(1):109-119.e6. PMID: 29155097.
     
Showing 10 of 167 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 167 publications over 29 distinct years, with a maximum of 17 publications in 2016

YearPublications
19881
19897
19908
19919
19921
19932
19944
19961
19971
19982
19992
20001
20024
20031
20043
20052
20067
20078
20084
20098
201014
20115
201210
201310
20149
20159
201617
20179
20188
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Lafyatis's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department